FOR SHAREHOLDERS

2021 Open Letter to Shareholder

VIEW MORE

Investor Presentation

VIEW PRESENTATION

More details for transparency

Should you invest in CBD?

We do not undertake to make any financial forecasts, but take a look at our field of activity, we do believe in the CBD industry and its future development. We are not the only ones who are so optimistic about it. CBD-related products have been increasingly popular over the recent few years. And it’s been happening for a reason. CBD doesn’t get users high and has an ability to treat multiple conditions and diseases. Apart from that, the U.S. DEA has officially removed the CBD with little to no THC from their list of controlled substances. The research conducted by the Brightfield Group and based impending regulatory changes in EU, the European CBD market is expected to be worth $1.7 billion by 2023. The cannabis market in general is also set to experience rapid growth, from $318 million in 2018 to nearly $8 billion by 2023.
According to forecasts from BDS Analytics and Arcview Market Research, the aggregate market for CBD sales in the US should exceed $20 billion by 2024. BDS Analytics predicts 49 percent compound annual growth by 2024, and the market for CBD combined with THC products is estimated at $45 billion by 2024.

Can we increase the transparency of the deal?

Sure. Cannabis Suisse Corp. is a fully reporting company and all our financials and disclosures are available on both SEC and OTC websites. You can also find all the links in financial reporting and disclosures section of our website. Our CUSIP is 13767A103. The information about our independent auditors and the transfer agent is publicly available and can be found on OTC website as well. The ticker symbol we are listed under is CSUI. We cannot comment on a move of our shares price or predict anything, however you can always see our stock quote below in real time.

Stock Quote